Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29


Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.

Park B, Sohn JY, Yoon KA, Lee KS, Cho EH, Lim MC, Yang MJ, Park SJ, Lee MH, Lee SY, Chang YJ, Lee DO, Kong SY, Lee ES.

Breast Cancer Res Treat. 2017 May;163(1):139-150. doi: 10.1007/s10549-017-4142-7. Epub 2017 Feb 15.


Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO.

Peng G, Bojadzieva J, Ballinger ML, Li J, Blackford AL, Mai PL, Savage SA, Thomas DM, Strong LC, Wang W.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):837-844. doi: 10.1158/1055-9965.EPI-16-0695. Epub 2017 Jan 30.


A two-stage approach to genetic risk assessment in primary care.

Biswas S, Atienza P, Chipman J, Blackford AL, Arun B, Hughes K, Parmigiani G.

Breast Cancer Res Treat. 2016 Jan;155(2):375-83. doi: 10.1007/s10549-016-3686-2. Epub 2016 Jan 19.


Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry.

Dite GS, MacInnis RJ, Bickerstaffe A, Dowty JG, Allman R, Apicella C, Milne RL, Tsimiklis H, Phillips KA, Giles GG, Terry MB, Southey MC, Hopper JL.

Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):359-65. doi: 10.1158/1055-9965.EPI-15-0838. Epub 2015 Dec 16.


Recent Enhancements to the Genetic Risk Prediction Model BRCAPRO.

Mazzola E, Blackford A, Parmigiani G, Biswas S.

Cancer Inform. 2015 May 10;14(Suppl 2):147-57. doi: 10.4137/CIN.S17292. eCollection 2015. Review.


Recent BRCAPRO upgrades significantly improve calibration.

Mazzola E, Chipman J, Cheng SC, Parmigiani G.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1689-95. doi: 10.1158/1055-9965.EPI-13-1364. Epub 2014 Jun 2.


Frailty Models for Familial Risk with Application to Breast Cancer.

Gorfine M, Hsu L, Parmigiani G.

J Am Stat Assoc. 2013 Dec 1;108(504):1205-1215.


Providing access to risk prediction tools via the HL7 XML-formatted risk web service.

Chipman J, Drohan B, Blackford A, Parmigiani G, Hughes K, Bosinoff P.

Breast Cancer Res Treat. 2013 Jul;140(1):187-93. doi: 10.1007/s10549-013-2605-z. Epub 2013 Jun 23.


Simplifying clinical use of the genetic risk prediction model BRCAPRO.

Biswas S, Atienza P, Chipman J, Hughes K, Barrera AM, Amos CI, Arun B, Parmigiani G.

Breast Cancer Res Treat. 2013 Jun;139(2):571-9. doi: 10.1007/s10549-013-2564-4. Epub 2013 May 21.


Identifying people at a high risk of developing pancreatic cancer.

Klein AP.

Nat Rev Cancer. 2013 Jan;13(1):66-74. doi: 10.1038/nrc3420. Epub 2012 Dec 6. Review.


The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers.

Mazzola E, Cheng SC, Parmigiani G.

Breast Cancer Res Treat. 2013 Jan;137(1):315-8. doi: 10.1007/s10549-012-2345-5. Epub 2012 Nov 27.


Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases.

Mercado RC, Hampel H, Kastrinos F, Steyerberg E, Balmana J, Stoffel E, Cohn DE, Backes FJ, Hopper JL, Jenkins MA, Lindor NM, Casey G, Haile R, Madhavan S, de la Chapelle A, Syngal S; Colon Cancer Family Registry.

Genet Med. 2012 Jul;14(7):670-80. doi: 10.1038/gim.2012.18. Epub 2012 Mar 8.


The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases.

Zanna I, Rizzolo P, Sera F, Falchetti M, Aretini P, Giannini G, Masala G, Gulino A, Palli D, Ottini L.

Eur J Hum Genet. 2010 Jul;18(7):856-8. doi: 10.1038/ejhg.2010.29. Epub 2010 Mar 17.


Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO.

Wang W, Niendorf KB, Patel D, Blackford A, Marroni F, Sober AJ, Parmigiani G, Tsao H.

Cancer Res. 2010 Jan 15;70(2):552-9. doi: 10.1158/0008-5472.CAN-09-2653. Epub 2010 Jan 12.


Penetrance of HNPCC-related cancers in a retrolective cohort of 12 large Newfoundland families carrying a MSH2 founder mutation: an evaluation using modified segregation models.

Kopciuk KA, Choi YH, Parkhomenko E, Parfrey P, McLaughlin J, Green J, Briollais L.

Hered Cancer Clin Pract. 2009 Oct 28;7(1):16. doi: 10.1186/1897-4287-7-16.


Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States.

Huo D, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, Hope K, Olopade OI.

J Clin Oncol. 2009 Mar 10;27(8):1184-90. doi: 10.1200/JCO.2008.17.5869. Epub 2009 Feb 2. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262.


Tailoring BRCAPRO to Asian-Americans.

Chen S, Blackford AL, Parmigiani G.

J Clin Oncol. 2009 Feb 1;27(4):642-3; author reply 643-4. doi: 10.1200/JCO.2008.20.6896. Epub 2008 Dec 15. No abstract available.


Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction.

Tai YC, Chen S, Parmigiani G, Klein AP.

Breast Cancer Res. 2008;10(2):401. doi: 10.1186/bcr1866. Epub 2008 Mar 20. No abstract available.


Multiple diseases in carrier probability estimation: accounting for surviving all cancers other than breast and ovary in BRCAPRO.

Katki HA, Blackford A, Chen S, Parmigiani G.

Stat Med. 2008 Sep 30;27(22):4532-48. doi: 10.1002/sim.3302.


Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.

Tai YC, Domchek S, Parmigiani G, Chen S.

J Natl Cancer Inst. 2007 Dec 5;99(23):1811-4. Epub 2007 Nov 27.

Supplemental Content

Support Center